Niraparib tosylate hydrate (also known as MK-4827; MK4827; Zejula), the tosylate
salt and hydrated form of niraparib, is a selective inhibitor of
PARP1/2 (IC50 = 3.8 nM and 2.1nM) that was approved by FDA for the treatment of recurrent epithelial ovarian, fallopian tube,
or primary peritoneal cancer.
纯度:≥98%
CAS:1613220-15-7